Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses.

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

Findings reveal fluoxetine's weak antiviral effects in COVID-19, with no significant benefits in symptom resolution compared to other antiviral treatments.

The study also evaluated the effectiveness of public health measures, such as travel restrictions, in reducing the spread ...

The Health sector expects the Finance Minister to prioritise healthcare in the upcoming Budget while the country works to ...

Quotient Therapeutics, a biotech company founded in 2022, hopes to take this transatlantic model and commercialise it. Its main research lab is in Great Chesterford, a village just outside Cambridge, ...

MSK researchers are helping to map the landscape of viruses that infect us all, and to analyze the impact they have on human health and disease.

Inside, between rows of incubators and microscopes, Beth Shapiro and her team are attempting a feat straight out of science ...

This rising trend mirrors the evolution of the pharmaceutical industry in terms of investment and utilisation of novel ...